美国Medicaid项目抗肥胖药物支出、利用和价格趋势：1999-2023年实证分析 Data Sheet 1

数据集获取（Figshare）

• 源站标题：Data Sheet 1_Spending, utilization, and price trends for anti-obesity medications in U.S. Medicaid programs: an empirical analysis from 1999 to 2023.docx
• DOI：10.3389/fmed.2025.1537181.s001
• 发布日期：2025-07-16
• 文件数：1 个
• 文件总体积：2.55 MB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/Data_Sheet_1_Spending_utilization_and_price_trends_for_anti-obesity_medications_in_U_S_Medicaid_programs_an_empirical_analysis_from_1999_to_2023_docx/29580107

命令行下载

curl -L -o "Data Sheet 1_Spending, utilization, and price trends for anti-obesity medications in U.S. Medicaid programs: an empirical analysis from 1999 to 2023.docx" "https://ndownloader.figshare.com/files/56309249"

文件清单

• Data Sheet 1_Spending, utilization, and price trends for anti-obesity medications in U.S. Medicaid programs: an empirical analysis from 1999 to 2023.docx（2.55 MB）

文件总体积 2.55 MB（源站 API 实测）。

数据说明

BackgroundObesity poses a significant public health and economic challenge in the United States (U.S.), with rising prevalence, particularly among individuals enrolled in Medicaid—the nation’s public health insurance program for low-income populations. Anti-obesity medications (AOMs) have become integral to managing obesity, but trends in their utilization and spending within Medicaid remain underexplored.
ObjectiveTo examine Medicaid’s utilization, reimbursement, and price trends for AOMs from 1999 to 2023.
MethodsA retrospective analysis assessing the utilization, reimbursement, and pricing of older and newer AOMs. Yearly prescription numbers and reimbursement were calculated for seven AOMs billed through Medicaid between 1999 and 2023. The average expenditure per prescription was used as an indicator of drug pricing.
ResultsAOM prescriptions rose from 13,855 in 1999 to 938,663 in 2023, a 6,674% increase. Spending surged by over 77,805,466% due to the introduction of newer, more effective medications, including Wegovy and tirzepatide. The largest share of the market growth in 2023 was driven by these medications.
ConclusionThe significant increase in AOM utilization and spending highlights the growing burden of obesity on Medicaid, emphasizing the need for policy measures to manage rising costs and ensure equitable access to treatment.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fmed.2025.1537181.s001（source: https://frontiersin.figshare.com/articles/dataset/Data_Sheet_1_Spending_utilization_and_price_trends_for_anti-obesity_medications_in_U_S_Medicaid_programs_an_empirical_analysis_from_1999_to_2023_docx/29580107）。